NuCana, a UK biotech developing enhanced chemotherapies for resistant tumors, announced terms for its IPO on Monday.
The Edinburgh, United Kingdom-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, NuCana would command a market value of $526million.
NuCana was founded in 2008 and plans to list on the Nasdaq under the symbol NCNA. Citi, Jefferies and Cowen & Company are the joint bookrunners on the deal. It is expected to price during the week of September 25, 2017.
